Because of the rule change between Pettachi & Froome obviously Merckx. Pettachi's couldn't be further adjusted like Froomes, because that part of the rule hadn't yet been created had it.
Conclusion/implication The present study shows that beta2-agonists do not affect aerobic performance in non-asthmatic subjects regardless of type, dose, administration route, duration of treatment or performance level of participants. The results of the present study should be of interest to WADA and to anyone who is interested in equal opportunities in competitive sports.